{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Maximum grade 2 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Maximum grade 4 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Immune-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Tremelimumab-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Durvalumab-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Serious TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"TEAE Leading to Treatment Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"TEAE Meeting DLT Criteria"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Toxicity was graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Treatment-emergent adverse events (TEAEs) were reported based on clinical laboratory tests, physical examinations, and vital signs from the time of enrollment through the end of the study period. DLTs were assessed from the first dose of study drug through the Cycle 2 administration of tremelimumab ± durvalumab post ASCT. DLTs were defined per protocol as lack of neutrophil/platelet engraftment by Day 30 post ASCT; Grade 5 toxicity (treatment-related death); Grade 4 non-hematological toxicity; Grade 3 non-hematological toxicity (with exclusions); isolated Grade 3 electrolyte abnormalities; or immune-related AEs resulting in discontinuation of treatment.","groups":[{"description":"\"Late\" post-ASCT treatment (tremelimumab alone in Cycles 1-2, durvalumab alone in Cycles 3+)","id":"OG000","title":"Cohort 1"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated subjects.","reportingStatus":"POSTED","timeFrame":"up to 14 months","title":"Number of Subjects With Treatment-emergent Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}